Tandem Diabetes Care, Inc. (TNDM) |
| 20.43 -0.13 (-0.63%) 09-03 16:00 |
| Open: | 20.71 |
| High: | 20.91 |
| Low: | 20.03 |
| Volume: | 1,593,475 |
| Market Cap: | 1,400(M) |
| PE Ratio: | -21.97 |
| Exchange: | NASDAQ Global Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 24.81 |
| Resistance 1: | 21.85 |
| Pivot price: | 21.96 |
| Support 1: | 17.07 |
| Support 2: | 14.20 |
| 52w High: | 29.65 |
| 52w Low: | 11.46 |
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
| EPS | -0.900 |
| Book Value | 1.880 |
| PEG Ratio | 0.00 |
| Gross Profit | 8.383 |
| Profit Margin (%) | -6.08 |
| Operating Margin (%) | -5.42 |
| Return on Assets (ttm) | -2.7 |
| Return on Equity (ttm) | -48.0 |
Wed, 02 Sep 2026
A Look at Tandem Diabetes Care Inc (TNDM) After 3.4% Decline -- GF Value $24.05 vs Price $20.56 - GuruFocus
Fri, 28 Aug 2026
TANDEM DIABETES CARE INC (TNDM) Stock Chart - ChartMill
Tue, 25 Aug 2026
Tandem Diabetes Care (TNDM) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - qz.com
Wed, 19 Aug 2026
How Tandem’s Q2 Loss and Pharmacy Pivot Will Impact Tandem Diabetes Care (TNDM) Investors - simplywall.st
Tue, 18 Aug 2026
Tandem Diabetes (NASDAQ: TNDM) EVP issued 2,827 shares, 809 withheld - Stock Titan
Tue, 18 Aug 2026
Tandem Diabetes (NASDAQ: TNDM) exec nets 475 shares after RSU vesting - Stock Titan
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |